myeloproliferative disorder clonal evolution clonal evolution & stepwise progression to fibrosis,...
DESCRIPTION
3 CML. Historical vs. Modern Perspective ParameterHistoricalModern CourseFatalIndolent PrognosisPoorExcellent 7-yr survival40%90% Frontline Rx Allogeneic SCT; IFN- Imatinib Second line Rx? New Tyrosine Kinase Inhibitors; allo SCT